Trabectedin registry;Lékový registr - Trabectedin

Klinicka Onkologie

Volumn 24, Issue 6, 2011, Pages 470-474

  Kubackova K ^a   Finek J ^b   Vyzula, R ^c   Zvarikova M ^c   Vocka M ^d   Batko, S ^a   Dreslerova J ^b   Lazarov, P P ^e   Lysy M ^f   Ptackova Z ^g   Benesova V ^h   Bortlicek Z ⁱ   Kandrnal, Vit ⁱ  

^a UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e Krajska Nemocnice Liberec   (Czech Republic)

^f Interní odd lení Klinika kardiologie Masarykova nemocnice v Ústí nad Labem   (Czech Republic)

^g UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^h Nemocnice Jihlava   (Czech Republic)

ⁱ MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Chemotherapy; Soft tissue sarcoma; Trabectedin; Treatment

Indexed keywords

TRABECTEDIN;

ADULT; AGED; ARTICLE; CANCER CENTER; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER REGISTRY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DATA BASE; HEALTH CARE; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NON PROFIT ORGANIZATION; ONCOLOGY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SIDE EFFECT; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CZECH REPUBLIC; DIOXOLES; HUMANS; MIDDLE AGED; REGISTRIES; SARCOMA; TETRAHYDROISOQUINOLINES; YOUNG ADULT;

EID: 84455194180     PISSN: 0862495X     EISSN: 18025307     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Carter NJ, Keam SJ. Trabectidin: a review of its use in soft tissue sarcoma and ovarian cancer. Drugs 2010; 70(3): 355-376.
2. Chuk MK, Balis FM, Fox E. Trabectedin. Oncologist 2009; 14(8): 794-799.
3. Schöffski P, Dumez H, Wolter P et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008; 9(9): 1609-1618. (Pubitemid 352005920)
4. Blay JY, von Mehren M, Samuels BK et al. Phase I combination study of trabectidin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008, 14(20): 6656-6662.
5. Clark MA, Fisher C, Judson I et al. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353(7): 701-711. (Pubitemid 41175678)
6. Hogendoorn PC, Collin F, Daugaard S et al. Changing concepts in the pathological basis of soft tissue and bone sarcoma treatment. Eur J Cancer 2004; 40(11): 1644-1654. (Pubitemid 38902898)
7. Veselý K. Histopatologická diagnostika nádorů měkkých tkání. Ontologie 2010; 4(5): 293-296.
8. Cormier JN, Pollock RE. Soft tissue sarcomas. CA Cancer J Clin 2004; 54(2): 94-109. (Pubitemid 38519419)
9. Dušek L, Mužík J, Kubásek M et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita 2005 [cit. 2011-4-27]. Dostupný z http://www.svod.cz.
10. Yondelis Summary of Product Characteristics SPC. EMA 2010. Available from: http://www.ema.europa.eu/docs/cs-CZ/document-library/EPAR-Product- Information/human/000773/WC500045832.pdf.
11. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27(25): 4188-4196.
12. Vyzula R et al. Zásady cytostatické léčby maligních onkologických onemocnění. 13. vydání. Brno: Masarykův onkologický ústav 2011.
13. Casali PG, Blay JY. ESMO/CONTICANET/EUROBONET Consensus Panel of Experts. Soft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl 5): v198-v203.
14. Schöffski P, Taron M, Jimeno J et al. Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: a retrospective multicentric study. Eur J Cancer 2011; 47(7): 1006-1012.
15. Ray-Coquard I. An increasing role for trabectidin in gynecological cancers: efficacy in uterine sarcomas. Int J Gynecol Cancer 2011; 21 (10 Suppl 1): S3-S5.
16. Scurr M. Histology-driven chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol 2011; 12(1): 32-45.